Insights from industry

Finding Their Natural Home - NanoSight's Acquisition by Malvern

Jeremy Warren, General Manager of NanoSight, talks to AZoNano about the recent acquisition of NanoSight by Malvern Panalytical.

It’s an exciting time for NanoSight, with the recent announcement of your acquisition by Malvern Panalytical. Can you tell us a bit about how this move came about?

It is a very exciting time.  We went through a complex process over the course of a year, trying to understand where NanoSight’s value was and where we best fitted. Malvern Panalytical was the obvious choice to many both within the organization and outside, but we spent a long time convincing ourselves that that was the case.

I’m now more convinced than ever that Malvern Panalytical is our natural home.  This move is right for our technology, its right for our people - and  I think the position that we're in now make us a formidable proposition, which I wouldn't like to have to compete with, myself.


NanoSight's NS300 nanoparticle characterization system with enhanced fluorescence capability

So the process took about a year – was this option in the pipeline before then?

We’ve been talking to Malvern Panalytical for years. I think we first talked to Malvern Panalytical in 2006.

This was never a foregone conclusion – we could have gone to someone else. The more we look at this though, now we’re in here, the more it feels exactly the right thing to have done.

So was this sort of move always on the cards for NanoSight, since the company formed in 2002?

Yes, NanoSight was a venture backed company, so the investors were always looking for exit opportunities.

What is it about NanoSight’s technology that makes it such a good fit within Malvern Panalytical?

Malvern Panalytical acquired us because we have unique technology – Nanoparticle Tracking Analysis - which serves expanding markets, mainly in the biopharma area.  Whilst there is a small overlap with Malvern Panalytical’ DLS technology, Dynamic Light Scattering, we’ve always positioned ourselves as complementary.

For Malvern Panalytical this is a great opportunity for growth, and for increasing access to the biopharma markets.

Jeremy Warren with Paul Walker, Managing Director at Malvern Panalytical

Jeremy Warren with Paul Walker, Managing Director at Malvern Panalytical

What are the main benefits of the acquisition from NanoSight’s point of view?

From our point of view, there are two major gains which we are excited about. One is the depth and scope of Malvern Panalytical’s capabilities in engineering and development. Their approach to producing robust tools is more mature than ours is. For NanoSight to be able to get much bigger, much faster, and to become a volume producer on the global market, we need that systems experience and infrastructure rigor.

The second thing is Malvern Panalytical’s channels to market, which are very impressive, and again are more mature and robust than what was available to NanoSight alone.

Is there a particular growth area you will be focusing on now you are part of Malvern Panalytical – expanding into new markets, or developing your technology further?

All those things, really.  There is lots of opportunity in terms of new products and new markets from both camps. The onus is now on us to make the very best decisions we can in taking this forward.

It seems there is a very positive feeling about the acquisition within NanoSight.

Certainly, and increasingly. This has given the people at NanoSight an opportunity to reflect on what we've been able to create, and I think that, to a man, people are justifiably proud of where we've got to – and from this point, the Malvern Panalytical move looks like a very good way to go forward from everybody's point of view.

In addition to the opportunities for the business as a whole, I think Malvern Panalytical presents significant personal opportunity for the people working at NanoSight. It's a larger organization with more opportunity within it and I think that's great.

Bob Carr, the founder of this business, has summed it up the best I think – he said that Malvern Panalytical is our natural home. That certainly rings true for me as well.

About Jeremy Warren

Jeremy Warren served as CEO of NanoSight Ltd for 9 years, and will continue as General Manager of NanoSight as part of Malvern Panalytical.

Jeremy WarrenNanoSight's Nanoparticle Tracking Analysis technology (NTA) can track and perform multi-parameter characterization of nanomaterials in suspension on a particle-by-particle basis.

The acquisition of NanoSight by Malvern Panalytical was completed on the 27th September, 2012.

For more information on NanoSight's technology, please visit their website.

Disclaimer: The views expressed here are those of the interviewee and do not necessarily represent the views of Limited (T/A) AZoNetwork, the owner and operator of this website. This disclaimer forms part of the Terms and Conditions of use of this website.

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Malvern Panalytical. (2024, March 01). Finding Their Natural Home - NanoSight's Acquisition by Malvern. AZoNano. Retrieved on May 23, 2024 from

  • MLA

    Malvern Panalytical. "Finding Their Natural Home - NanoSight's Acquisition by Malvern". AZoNano. 23 May 2024. <>.

  • Chicago

    Malvern Panalytical. "Finding Their Natural Home - NanoSight's Acquisition by Malvern". AZoNano. (accessed May 23, 2024).

  • Harvard

    Malvern Panalytical. 2024. Finding Their Natural Home - NanoSight's Acquisition by Malvern. AZoNano, viewed 23 May 2024,

Ask A Question

Do you have a question you'd like to ask regarding this article?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.